We previously demonstrated the doxorubicin-induced urokinase-type plasminogen activator (uPA) expression in human RC-K8 lymphoma cells and NCI-H69 small cell lung carcinoma cells in which reactive oxygen species might be involved. Western blotting analysis revealed phosphorylation/activation of mitogen-activated protein (MAP) kinases, such as extracellular signal-regulated kinase (ERK) 1/2, p38 MAP kinase and stress-activated protein kinase/c-jun N-terminal protein kinase (SAPK/ JNK) in doxorubicin-treated RC-K8 and H69 cells, and, therefore, we attempted to identify the MAP kinases implicated in doxorubicin-induced uPA expression by the use of their specific inhibitors. U0126, SB202190 and JNKI-1, inhibitors for MAPK kinase, (MEK) 1/2, p38 MAP kinase and SAPK/JNK, respectively, specifically and clearly inhibited their corresponding kinases. U0126 and SB202190, but not JNKI-1, almost completely inhibited the doxorubicin-induced uPA expression in both RC-K8 and H69 cells. However, U0126 rather enhanced the doxorubicin-induced activation of caspase-3 and poly ADP-ribose polymerase (PARP), and U0126 itself activated caspase-3 and PARP. Interestingly, JNKI-1 inhibited the doxorubicin-induced activation of caspase-3 and PARP. Therefore, doxorubicin treatment activates the above three kinases, but different MAP kinase signaling is responsible in the doxorubicin-induced caspase activation and expression of uPA. Thus, we could possibly manipulate the direction of doxorubicin-induced MAP kinase activation and the effects of doxorubicin on the tumor cell biology by the use of MAP kinase inhibitors.
Introduction
Anthracyclines possibly generate reactive oxygen species (ROS) in the cells and induce apoptosis of human malignant cells. Doxorubicin, one of the anthracyclines, is the most widely used anticancer agent and a key drug for the treatment of malignant lymphoma and small cell lung cancer (SCLC) [1, 2] . We, therefore, examined effects of doxorubicin on the cell growth and gene expression in a number of malignant lymphoma cell lines and SCLC cell lines. Among the cell lines examined, we have found that doxorubcin-induced urokinase-type plasminogen activator (uPA) expression in two human malignant cell lines, RC-K8 lymphoma cells and NCI-H69 SCLC cells [3, 4] . The maximum induction was observed at 'sublethal' concentrations of doxorubicin where cell growth was slightly inhibited, which is a clinically achievable concentration [5, 6] . However, the significance of uPA in tumor biology is not fully understood. uPA facilitates the potential of metastasis by degrading extracellular matrix [7, 8] , and is thought to be one of the poor prognostic factors in human malignancy [8] . On the other hand, uPA may strengthen the antitumor effects of doxorubicin, especially when secreted during chemotherapy, because detached malignant cells from matrix become more sensitive to antitumor drugs [9] .
The implication of mitogen-activated protein (MAP) kinases, such as stress-activated protein kinase, also known as c-jun N-terminal protein kinase (SAPK/JNK) and/or extracellular signal-regulated kinase (ERK)1/2, was reported in uPA induction by UV irradiation [10] and stimulation with phorbol ester [11] where ROS is possibly involved. Furthermore, doxorubicin induced apoptosis through caspase activation [12, 13] , where the role of MAP kinase signaling was demonstrated. However, the types of MAP kinase involved in the doxorubicin-induced apoptosis appear to be rather cell-type specific; SAPK/JNK pathway was shown to be the most important in the doxorubicininduced apoptosis of H4IIE hepatoma cells [14] , both SAPK/JNK and p38 MAP kinase were in KB-3 carcinoma cells [15] , p38 MAP kinase was in NIH 3T3 fibroblasts [16] , but ERK was in neuroblastoma cells [17] . Thus, a better understanding of the MAP kinase signaling occurring in doxorubicin-treated cells undoubtedly helps to develop new drugs for the further improvement of cancer chemotherapy, and it is very interesting to note whether the same MAP kinase signaling pathway is used in uPA expression and apoptosis induced by doxorubicin treatment. We initially examined activation of the MAP kinases by Western blotting staining using specific antibodies against the MAP kinases, and confirmed phosphorylation and activation of all three MAP kinases in doxorubicin-treated RC-K8 and H69 human lung carcinoma cells. Then, we further examined the involvement of these kinases in the doxorubicin-induced uPA expression and caspase activation by the use of their specific inhibitors. Here, we demonstrate that different MAP kinase signalings are implicated in doxorubicin-induced uPA expression and caspase activation in two human malignant cells.
Materials and Methods

Materials
Doxorubicin was purchased from Sigma (St. Louis, Mo., USA). Specific inhibitors against MAPK kinase (MEK)1/2 and p38 MAP kinase, 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126) and 4-(4-fluorophenyl)2-(4-hydroxyphenyl)5-(4-pyridyl)1H-imidazole (SB202190), respectively, and their negative control reagents, 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene; a negative control for U0126 (U0124) and a negative control for SB202190 (SB202474) were purchased from Calbiochem (La Jolla, Calif., USA). A specific inhibitor against SAPK/JNK, JNKI-1 and its control peptide, JNKI-1CP, were obtained from BioVision (Mountain View, Calif., USA). A pan caspase inhibitor, z-Val-AlaAsp(OMe)-CH 2 F, was obtained from Calbiochem (San Diego, Calif., USA).
Cell Lines and Culture
Human RC-K8 lymphoma cells [18] and NCI-H69 (ATCC HBT-119) SCLC cells were grown in RPMI-1640 culture medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum (Whittaker Bioproducts, Walkersville, Md., USA), 100 U/ml penicillin and 100 Ìg/ml streptomycin, and cells were washed once with phosphate buffered saline, and resuspended in serum-free RPMI-1640 (at approximately 1-2 ! 10 6 /ml). In this study, cells were pretreated with one of the MAP kinase inhibitors for 1 h and then exposed to doxorubicin for 1 h. Cells washed once with serum-free RPIM-1640 were further cultured in serum-free RPMI-1640 in a 24-well culture plate (1 ml/well) or 6-well culture plate (5 ml/well) in a 5% CO 2 incubator. The number of surviving and proliferating cells was measured by the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tertrazolium bromide (MTT) assay for mitochondrial dehydrogenese enzyme activity as described by Mosmann [19] . The correlation curve between viable cell numbers, counted by the trypan blue dye exclusion method, and the amount of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tertrazolium bromide formazan generated was used to measure the cell number. However, it does not obviously reflect the correct cell number, and, therefore, results were expressed as cell density (% relative to untreated controls). The annexin V-positive staining, which detects phosphatidylserine exposed to the outer cell membrane during apoptosis, was used for the detection of apoptosis by flow cytometry (Medical & Biological Laboratories, Nagoya, Japan).
uPA Activity Assay uPA activities in the cultured supernatant obtained 24-48 h after exposure to doxorubicin were measured using a synthetic uPA substrate, S-2444 [18] , and a plasminogen-containing fibrin plate (fibrin zymography) as previously described [20] . Cultured supernatants were collected and stored at -80°C before use.
Northern Blot Analysis uPA mRNA levels were detected by Northern blotting. Briefly, cells were pretreated with one of the MAP kinase inhibitors for 1 h and exposed to doxorubicin for 1 h. Then, cells were washed once with the RPMI-1640 culture medium and further cultured for 8 h. Total RNA was isolated by the acid guanidinium thiocyanate-phenol-chloroform method and 10 Ìg of total RNA was subjected to Northern blot analysis as described by Sambrook et al. [21] . A cDNA probe for uPA was labeled with 32 P-dCTP by a random-primed DNA-labeling technique. mRNA levels were quantified by counting Niiya/Niiya/Shibakura/Asaumi/Yoshida/ Shinagawa/Teshima/Ishimaru/Ikeda radioactivity using a BAS 2000 imaging analyzer (Fuji-film, Tokyo). As control for difference in RNA sample loading, filters were rehybridized with a radiolabeled ß-actin cDNA probe.
Immunodetection of Phosphorylated MAP Kinases and Activated Caspases
Phosphorylated MAP kinase was detected by Western immunoblotting using specific polyclonal antibodies against phosphorylated ERK1/2, p38 MAP kinase and SAPK/JNK. Cleaved and uncleaved caspases were also detected by Western immunoblotting using specific polyclonal antibodies against caspase-3, -7, -9 and PARP. Briefly, a total of 1 ! 10 7 cells were washed with ice-cold phosphatebuffered saline and lysed in 500 Ìl of cell lysis buffer (20 mM TrisHCl at pH 7.5, 150 mM NaCl, 1 mM EDTA, 1mM EGTA, 1% Triton X-100, 1 mM ß-glycerophosphate, 2.5 mM Na pyrophosphate, 1 mM Na 3 VO 4 , 1 mM PMSF, 1 Ìg/ml leupeptin) on ice for 5 min. After sonication, nuclei-free supernatant was obtained by centrifugation at 10,000 rpm for 10 min at 4°C. Protein concentration of the supernatant was measured using the protein assay reagent (Bio-Rad, Hercules, Calif., USA). Twenty micrograms of protein were loaded per lane, separated by SDS-PAGE on a 10% gel under reducing condition, and were electrophoretically blotted onto the Immobilon TM PVDF transfer membrane (Nihon Millipore, Yonezawa, Japan). Immunodetection was performed using rabbit polyclonal antibodies against phospho-p44/42 ERK1/2 (Thr202/Tyr204), phospho-p38 MAP kinase (Thr180/Tyr182), phospho-SAPK/JNK (Thr183/ Tyr185), caspase-3, cleaved caspase-3 (Asp175), caspase-7, cleaved caspase-7 (Asp198), caspase-9, cleaved caspase-9 (Asp330), PARP and cleaved PARP (Asp214) (Cell Signaling Technology, Beverly, Mass., USA) as the first antibody. Mouse monoclonal antibodies against ERK1, ERK2, p38· MAP kinase and c-Jun (BD Biosciences, Tokyo, Japan) were also used as the first antibody. Equal loading was verified by immunodetecting the MAP kinase itself. After washing with Tris-buffered saline containing 0.1 % Tween 20, the membrane was treated with horseradish peroxidase-conjugated goat antirabbit secondary antibody (Cell Signaling Technology) or horseradish peroxidase-conjugated goat antimouse secondary antibody (Amersham Biosciences, N.J., USA). Immune complexes were visualized using ECL plus Western blotting detection reagents (Amersham Biosciences) and exposed to Hyperfilm TM ECL TM (Amersham Pharmacia Biotech, UK).
Western Blot Analysis for Detecting MAP Kinase Activity
Kinase activities, such as ERK1/2, p38 MAP kinase and SAPK/ JNK, were performed by Western blotting using monoclonal antibodies against phosphorylated substrate proteins. Briefly, whole-cell lysates were prepared as described previously in Methods, and protein concentration of the supernatants was measured by the protein assay system (Bio-Rad) as described previously, and was unified by dilution with the above cell lysis buffer. For detecting ERK1/2 and p38 MAP kinase activities, cell lysate (200 Ìl) was mixed with 15 Ìl of a monoclonal antibody raised against phospho-p44/42 ERK1/2 (Thr202/Tyr204) or phospho-p38 MAPK (Thr180/Tyr182) with protein A-Sepharose beads (Cell Signaling Technology), and the mixture was incubated at 4°C overnight. Then, the beads were washed twice with lysis buffer and twice with kinase buffer consisting of 25 mM Tris-HCl at pH7.5, 10 mM MgCl 2 , 5 mM ß-glycerophosphate, 0.1 mM Na 3 VO 4 , 2 mM DTT and 200 ÌM ATP, and resuspended in 50 Ìl of kinase buffer containing 2 Ìg of Elk-1 and ATF-2 (Cell Signaling Technology) that were specific substrates of active ERK1/2 and p38 MAP kinase, respectively, and incubated for 30 min at 30°C. For detecting SAPK/JNK activity, 250 Ìl of cell lysate was mixed with 20 Ìl of c-jun protein conjugated beads (Cell Signaling Technology) for 30 min at 30°C; c-jun is a specific substrate protein of active SAPK/JNK. The reaction was terminated by adding 25 Ìl of 3 ! SDS sample buffer, and the samples were boiled for 5 min, microcentrifuged for 2 min and were resolved by 10% SDS-PAGE. After transferring onto Immobilon TM PVDF membrane (Nihon Millipore, Yonezawa, Japan), the membrane was incubated with rabbit polyclonal antibodies against phospho-Elk-1 (Ser383), phospho-ATF-2 (Thr71) or phospho-c-Jun (Ser63). After washing, membranes were incubated with horseradish peroxidase-conjugated goat antirabbit secondary antibodies (Cell Signaling Technology) and visualized by ECL detection system (Amersham Biosciences).
Statistical Analysis
Statistical analysis was done on a DOS/V computer (Sharp Computer, Tokyo, Japan). Values were expressed as the mean B SE. Statistical significance was determined using Student's t test to compare unpaired data.
Results
Doxorubicin-Induced Phosphorylation/Activation of MAP Kinases and Specific Inhibition of the Phosphorylation/Activation of MAP Kinases by Their Inhibitors
In our previous experiments, cells were continuously stimulated with doxorubicin for 24 or 48 h [3] , but tumor cells are only transiently exposed to doxorubicin in vivo because doxorubicin is usually administered to patients by an intravenous infusion and, therefore, doxorubicin rapidly disappears from the blood stream. Then, in this experiment, we treated cells with doxorubicin for 1 or 3 h, as described in Methods. Interestingly, 1-hour treatment resulted in the maximum induction of uPA, and cell viability was less affected (data not shown). Therefore, in the subsequent experiments, cells were exposed to doxorubicin for 1 h.
Phosphorylation and activation of ERK1/2 were investigated by Western blotting using specific antibodies against phosphorylated ERK1/2 and Elk-1 (a specific substrate for ERK1/2). Doxorubicin induced a time-dependent phosphorylation of both ERK1/2 and Elk-1 in RC-K8 cells (fig. 1a) . The peak induction was observed at 8 h after stimulation as shown in figure 1a, top and second panels. Protein levels of ERK 1 and 2 changed little between, before and after treatment with doxorubicin ( fig. 1a , third and bottom panels).
U0126, a specific inhibitor of MEK1/2 which resides just at the upper stream of the ERK1/2 pathway, completely inhibited the doxorubicin-induced phosphoryla- . a Time course of doxorubicin-induced phosphorylation of Elk-1, a specific substrate for ERK1/2. Kinase activities of ERK1/2 (top panel), phosphorylation of ERK1/2 (second panel) and protein levels of ERK1/2 (third and fourth panels) were examined by Western blotting using antibodies against phosphorylated Elk-1, a specific substrate for ERK1/2, phosphorylated ERK1/2, ERK1 and ERK2, respectively. Cell lysates were prepared from the doxorubicin-treated cells at the times shown in the figure, and an equal amount of protein (20 Ìg/lane) was loaded on the SDS-PAGE (10% polyacrylamide gel) as described in Methods. b Effects of U0126 on the doxorubicininduced phosphorylation of ERK1/2, p38 MAP kinase and SAPK/ JNK. RC-K8 cells pretreated for 1 h with 10 ÌM of either U0126 or its negative control reagent, U0124, were exposed to 2 ÌM doxorubicin for 1 h. Protein levels of ERK1/2, phosphorylated ERK1/2, phosphorylated p38 MAP kinase and phosphorylated SAPK/JNK in the 24-hour cultured medium were examined by Western blotting using their corresponding specific antibodies as described in Methods. . a Cell lysates (20 Ìg protein) obtained from the doxorubicintreated RC-K8 cells at the times shown in this figure were subjected to 10% polyacrylamide gel SDS-PAGE, and Western blottings using specific antibodies against phosphrylated ATF-2, a substrate protein for p38 MAP kinase, phosphorylated p38 MAP kinase and p38 MAP kinase itself were performed. b RC-K8 cells were pretreated with 1 ÌM of SB202190 or its negative control, SB202474, for 1 h, and then exposed to 2 ÌM doxorubicin for 1 h. After washing, cells were further cultured in doxorubicin-free culture medium for 7 h, and cell lysates were prepared and subjected to 10% SDS-PAGE as described in Methods.
Niiya/Niiya/Shibakura/Asaumi/Yoshida/ Shinagawa/Teshima/Ishimaru/Ikeda -1 (b) . a Western blotting using specific antibodies against phosphorylated c-jun, a substrate protein for SAPK/JNK, phosphorylated SAPK/JNK and c-jun was performed. b RC-K8 cells were pretreated with 10 ÌM of JNKI-1 or its control peptide JNKI-1CP for 1 h and then exposed to 2 ÌM doxorubicin for 1 h. After washing, cells were further cultured in doxorubicin-free culture medium for 7 h, and cell lysates were prepared and subjected to 10% SDS-PAGE as described in Methods.
tion of ERK1/2 ( fig. 1b, top panel) , but it did not inhibit p38 MAP kinase and SAPK/JNK phosphorylation ( fig. 1b , fourth and bottom panels) without affecting the protein levels of ERK1/2 (fig. 1b, second and third panels). U0124, a negative control for U0126, did not do anything about the doxorubicin-induced phosphorylation of the MAP kinases ( fig. 1b) .
Doxorubicin also induced activation and phosphorylation of p38 MAP kinase, and the peak was observed at 4 or 8 h after stimulation ( fig. 2a, top and middle panels) . Protein levels of p38 MAP kinase did not change during doxorubicin treatment ( fig. 2a, bottom panel) . SB202190, a specific inhibitor to p38 MAP kinase, clearly inhibited phosphorylation of p38 MAP kinase ( fig. 2b, top panel) without affecting the protein levels of p38 MAP kinase ( fig. 2b, second panel) , but it did not inhibit phosphorylation of either ERK1/2 or SAPK/JNK kinases ( fig. 2b , third and bottom panels). SB202474, a negative control of SB202190, had no effect ( fig. 2b) .
Doxorubicin induced activation and phosphorylation of SAPK/JNK and c-jun (a substrate of SAPK/JNK) without affecting c-jun protein levels ( fig. 3a, bottom panel) . As expected, its inhibitor, JNKI-1, specifically inhibited phosphorylation of SAPK/JNK but not that of other kinases ( fig. 3b , top, third and bottom panels) without affecting SAPK/JNK protein levels ( fig. 3b , second panel). JNK-1CP, a control peptide for JNKI-1, did not affect the doxorubicin-induced phosphorylation of MAP kinases. Thus, treatment with doxorubicin resulted in the phosphorylation of all three MAP kinases in RC-K8 cells, and the phosphorylated kinases were all active in their kinase activity. Each MAP kinase inhibitor only inhibited doxorubicin-induced phosphorylation and activation of its corresponding kinase. Very similar results were also obtained in H69 cells (data not shown).
Inhibition of Doxorubicin-Induced uPA Expression by MAP Kinase Inhibitors
To investigate the role of the MAP kinase signaling in doxorubicin-induced uPA expression, RC-K8 and H69 cells were pretreated with MAP kinase inhibitors for 1 h, and then exposed to doxorubicin. One hour after incubation, cells were washed once with serum-free RPMI-1640 and further cultured in a 5% CO 2 incubator. uPA activities in the conditioned medium, collected 24 h after stimulation, were measured as described in Methods. As shown in figure 4a, U0126, a specific inhibitor for MEK1/ 2, but not for U0124, a negative control, inhibited the doxorubicin-induced uPA accumulation in a dose-dependent manner with a slight reduction in cell density. SB202190, a specific inhibitor for p38 MAP kinase, also inhibited the doxorubicin-induced uPA expression in a dose-dependent manner, but SB202474, a negative control, did not, as shown in figure 4b . However, neither a b Fig. 4 . Effects of MAP kinase inhibitors on uPA accumulation and cell density in doxorubicin-treated RC-K8 cells. RC-K8 cells pretreated with MAP kinase inhibitors or their negative control reagents for 1 h were stimulated with 2 ÌM doxorubicin for 1 h, and then further cultured for 23 h. uPA activity in the conditioned medium and cell density were measured by a colorimetric assay using a synthetic uPA substrate, S-2444, and MTT method, respectively, as described in Methods. Cells were pretreated with varying concentrations of U0126 or its negative control U0124 (a), SB202190 or its negative control SB202474 (b), or JNKI-1 or its control peptide JNKI-1CP (c). The results are presented as the means B SD from four separate experiments. ** p ! 0.01 using Student's t test compared to values obtained from doxorubicin-treated cells. Cells were pretreated with 1 ÌM of SB202190, 1 ÌM of its negative control SB202472, 10 ÌM U0126 or 10 ÌM of its negative control U0124 for 1 h and then exposed to 2 ÌM doxorubicin for 1 h. After washing, cells were further cultured for 8 h, and total RNA was isolated. uPA mRNA levels were measured by Northern blotting as described in Methods. A ß-actin cDNA was used as an internal control.
JNKI-1, a specific inhibitor for SAPK/JNK, nor JNKI-1CP inhibited the doxorubicin-induced uPA expression, as shown in figure 4c . Next, we investigated the effects of MAP kinase inhibitors on uPA gene expression in RC-K8 cells. Northern blotting revealed the inhibition of the doxorubicin-induced uPA gene expression by either U0126 (10 ÌM) or SB202190 (1 ÌM) ( fig. 5 ), but JNKI-1 did not inhibit the doxorubicin-induced uPA expression (data not shown). Very similar results were also obtained in H69 cells (data not shown).
Niiya/Niiya/Shibakura/Asaumi/Yoshida/ Shinagawa/Teshima/Ishimaru/Ikeda Thus, these data suggest that ERK1/2 and p38 MAPK, but not SAPK/JNK, are implicated in doxorubicininduced uPA expression in both RC-K8 and H69 cells.
Effects of an Antioxidant, Pyrrolidine Dithiocarbamate (PDTC), on Doxorubicin-Induced Phosphorylation of MAP Kinases
In order to investigate the ROS involvement, we examined effects of an antioxidant, pyrrolidine dithiocarbamate (PDTC), on doxorubicin-induced phosphorylation of MAP kinases. Pretreatment with PDTC resulted in a clear inhibition of doxorubicin-induced phosphorylation of three MAP kinases as shown in figure 6 , suggesting the involvement of ROS in doxorubicin-induced phosphorylation of MAP kinases.
Doxorubicin-Induced Cleavage of Caspase Family
To investigate the MAP kinase signaling pathway involved in doxorubicin-induced cell-growth inhibition, we checked the cleavage of caspase family before and after doxorubicin treatment by Western blot technique. Caspase-3, caspase-9 and PARP, but not caspase-7, were cleaved 36-48 h after exposure to doxorubicin ( fig. 7) . Then, we performed annexin V staining to detect apoptotic cells in both RC-K8 and H69 cells. The percentage of annexin V-positive cells was approximately 5% in both cells, but it was increased to approximately 55% at 48 h after treatment with 2 ÌM doxorubicin in both cells (data not shown). Furthermore, the percentage of annexin V-positive cells was increased in a dose-and time-dependent manner with doxorubicin, and it appeared to be almost in parallel with cleavage of the caspase family (data not shown). Thus, we studied the relation between doxorubicin-induced caspase activation and cell death by the use of a pan-caspase inhibitor, z-Val-Ala-Asp(OMe)-CH 2 F [22] . H69 and RC-K8 cells were treated with doxorubicin (2 ÌM) in the presence of z-Val-Ala-Asp(OMe)-CH 2 F (100 ÌM) and cell viability was measured 48 h after exposure to doxorubicin, and it negated the doxorubicin-induced cell growth inhibition in both cells (data not shown). These results suggest that doxorubicin induces apoptosis through activating caspases in H69 and RC-K8 cells.
Next, we investigated the effects of MAP kinase inhibitors on the doxorubicin-induced cleavage of caspases. JNKI-1 inhibited the cleavage of caspase-3 and PARP ( fig. 8b) , whereas U0126 and SB202190 did not. Interestingly, U0126 itself cleaved caspase-3 and PARP (in fig. 8a ) and stimulated doxorubicin-induced cleavage of caspases ( fig. 8b ). These findings suggest that SAPK/JNK, but not ERK1/2 (MEK1/2) and p38 MAP kinase, is implicated in doxorubicin-induced activation of caspases.
Discussion
A number of previous studies have demonstrated the involvement of SAPK/JNK and/or ERK1/2 in uPA expression induced by 'stress' such as UV irradiation [10] , phorbol ester [11] or an alkylating agent, N-methyl-Nnitro-N-nitrosoguanidine (MNNG) [23] , that may use ROS as signaling messengers. For example, the murine uPA gene expression was transcriptionally upregulated by UV via the SAPK/JNK signaling pathway in NIH 3T3 fibroblasts and F9 teratocarcinoma cells [10] . Phorbol ester induced uPA expression in human ovarian cancer cells through the signaling pathway of MEK/ERK2 and c-jun [11] . In those reports, specific inhibitors against MAP kinases and/or dominant negative isoforms were used to inhibit the MAP kinase signaling pathways. In this Fig. 7 . Western immunoblot analysis of the time course of doxorubicin-induced cleavage of caspases in RC-K8 cells. RC-K8 cells were exposed to 2 ÌM doxorubicin for 1 h and then washed once with FCS-containing RPMI-1640. Cells were further cultured in FCS-containing RPMI-1640 medium, and whole cell lysates were prepared at the time shown in the figure. Loading protein levels were adjusted to 20 Ìg/lane and subjected to 10% SDS-PAGE. Western blotting analysis using specific antibodies to caspase-3, cleaved caspase-3, PARP, cleaved PARP, caspase-9, cleaved caspase-9, caspase-7 or cleaved caspase-7 was performed. Fig. 8 . Effects of MAP kinase inhibitors on doxorubicin-induced caspase activation in RC-K8 cells. a Direct effects of MAP kinase inhibitors on caspase activation were examined by Western blotting. Cells were treated with 10 ÌM U0126, 10 ÌM U0124 (a negative control), 1 ÌM SB202190, 1 ÌM SB202474 (a negative control), 10 ÌM JNKI-1 and 10 ÌM JNKI-1CP (a control peptide) for 1 h and washed once with FCS-containing RPMI-1640 medium. Cells were further cultured for 47 h in FCS-containing RPMI-1640 medium and whole cell lysates was obtained. Loading protein levels were adjusted to 20 Ìg/ lane and subjected to 10% SDS-PAGE, and Western blotting was performed. b After pretreatment with MAP kinase inhibitors, RC-K8 cells were exposed to 2 ÌM doxorubicin for 1 h and then washed once with FCS-containing RPMI-1640. Cells were cultured for 47 h in FCS-containing RPMI-1640 and whole-cell lysates were prepared and subjected to Western blotting.
Niiya/Niiya/Shibakura/Asaumi/Yoshida/ Shinagawa/Teshima/Ishimaru/Ikeda study, we also used the same MAP kinase inhibitors. As demonstrated here, we were able to confirm the specific inhibitory effects of the inhibitors; each inhibitor completely inhibited only the corresponding MAP kinase ( fig. 1-3) . Either a p38 MAP kinase inhibitor or an ERK1/2 inhibitor, but not a SAPK/JNK inhibitor, clearly inhibited the doxorubicin-induced uPA expression in RC-K8 cells, although phosphorylation of all three MAP kinases, including SAPK/JNK, was induced by doxorubicin treatment. Our previous experiments indicated the transcriptional regulation of both uPA expressions in RC-K8 and H69 cells [3] . Interestingly, the involvement of SAPK/JNK pathway was reported in the transcriptional uPA expression induced by UV irradiation [10] , and the involvement of ERK pathway was observed in basic fibroblast growth factorinduced uPA expression [24] . On the other hand, a role of p38 MAP kinase in regulating uPA mRNA stability was demonstrated in invasive breast cancer cells [25] , and treatment with a p38 MAP kinase inhibitor, SB203580, resulted in an inhibition of ·˘ integrin-mediated uPA mRNA. Thus, MAP kinase pathways may differently participate in doxorubicin-induced uPA gene expression.
SAPK/JNK signaling appears to be involved in the doxorubicin-induced cleavage of caspases, because only JNKI-1, a specific inhibitor to SAPK/JNK, but not other kinase inhibitors, inhibited the cleavage of caspases as shown in figure 8 , although involvement of all three MAP kinases in doxorubicin-induced apoptosis was demonstrated in different cell types, such as neuroblastoma cells [17] , fibroblasts from type A Niemann-Pick patients [26] and NIH 3T3 fibroblasts [16] . Interestingly, U0126, a specific inhibitor to ERK1/2, itself induced cleavage of caspases and enhanced doxorubicin-induced cleavage of caspases. Withdrawal of the nerve growth factor led to the sustained activation of the SAPK/JNK and inhibition of ERKs, and cytoprotective effect of ERK1/2 against NGF withdrawalinduced apoptosis was demonstrated in rat PC-12 pheochromocytoma cells [27] . Taken together, it is suggested that doxorubicin may induce apoptosis through the SAPK/ JNK pathway and cytoprotective signaling through the ERK1/2 pathway. Similar to our findings, the involvement of JNK in doxorubicin-induced apoptosis and potentiation of U0126 on the cytotoxic effects of doxorubicin were already demonstrated in KB-3 carcinoma cells [28] , suggesting that these findings were not cell-type specific.
Higher expression of uPA was observed in chemoresistant cancer cells [8] . uPA may initiate tumor metastasis by activating metalloproteinases and degrading the extracellular matrix [7, 8] . However, uPA may strengthen antitumor effects of doxorubicin, especially when secreted during chemotherapy, because detached malignant cells from the matrix become more sensitive to antitumor drugs [9] . Thus, combination chemotherapy with doxorubicin and a ERK1/2 inhibtor, U0126, may be a very attractive option. If uPA expression leads tumor cells to a more aggressive phenotype, doxorubicin and U0126 should be administered simultaneously, because U0126 inhibited uPA expression and facilitated caspase activation. If uPA expression strengthens the antitumor effects of doxorubicin, U0126 should be administered 24 h after the administration of doxorubicin, because the peak induction of uPA gene was observed at 9 h [3] (fig. 8) .
Recently, epidermal growth factor receptor tyrosine kinase inhibitor, ZD 1839, and Bcr-Abl tyrosine kinase inhibitor, STI-571, were successfully introduced for the treatment of patients with lung cancer and chronic myelogenous leukemia, respectively [29] [30] [31] [32] . Furthermore, phase I trials of MEK/MAP kinase inhibitor PD184352 in human malignancy is already ongoing [33] . Therefore, a better understanding of the MAP kinase pathway involved in doxorubicin-induced gene expression and apoptosis of tumor cells may provide novel approaches to improve cancer chemotherapy, and thus, we believe that our data described here add important information to the strategy of combination cancer chemotherapy.
Conclusion
Doxorubicin induced phosphorylation/activation of all three MAP kinases in RC-K8 lymphoma and H69 SCLC, but different signaling pathways were implicated in doxorubicin-induced caspase activation and expression of uPA: SAPK/JNK in caspase activation, both ERK1/2 and p38 MAP kinase in uPA expression. Furthermore, a specific ERK1/2 inhibitor, U0126, itself induced caspase activation and strengthened the doxorubicin-induced caspase activation. Thus, we could possibly manipulate the direction of doxorubicin-induced MAP kinase activation and the effects of doxorubicin on the tumor cell biology by the use of MAP kinase inhibitors.
